Join to view full profile
1515 Holcombe BlvdUnit 0455Houston, TX 77030
Phone+1 713-792-4318
Fax+1 713-745-3855
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Siqing Fu, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona.
Education & Training
University of Rochester Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Rochester Medical CenterResidency, Internal Medicine, 1999 - 2001
Yale-New Haven Medical CenterInternship, Internal Medicine, 1998 - 1999
Tongji Medical UniversityClass of 1985
Certifications & Licensure
CA State Medical License 2008 - Present
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2028
MS State Medical License 2023 - 2027
OK State Medical License 2020 - 2027
TN State Medical License 2023 - 2027
AL State Medical License 2023 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- 2 citationsLefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim
Journal of Immunotherapy and Precision Oncology. 2025-05-01 - Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic
Investigational New Drugs. 2025-04-01 - 4 citationsA Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.Omar Alhalabi, Mohamed A Gouda, Denái R Milton, Hassan Ahmed Momin, Bulent Yilmaz
Cancer Medicine. 2025-02-01
Press Mentions
Personalized Cancer Vaccines Are the Future of Cancer Treatment. Here’s How They WorkAugust 12th, 2024
MD Anderson Research Highlights for December 19, 2022December 19th, 2022
Soricimed Appoints Leading North American Cancer Researcher Dr. Siqing Fu to Its Scientific Advisory BoardDecember 13th, 2022















